Rank #1524RLMD

Relmada Therapeutics, Inc.

$4.36

6.86% (Daily)

Market Cap

$319.73M

Revenue

$N/A

Rank by MCap

#1524

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Sergio Traversa M.B.A., Pharm.D.

Headquarters

Coral Gables, FL

Employees

About Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, exces...